306,047 Shares in Vaxcyte, Inc. $PCVX Bought by Spruce Street Capital LP

Spruce Street Capital LP bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 306,047 shares of the company’s stock, valued at approximately $17,790,512,000. Vaxcyte comprises approximately 3.5% of Spruce Street Capital LP’s holdings, making the stock its 9th largest position.

A number of other institutional investors and hedge funds also recently bought and sold shares of PCVX. Smartleaf Asset Management LLC lifted its stake in Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after purchasing an additional 184 shares in the last quarter. Capital Advisors Ltd. LLC bought a new stake in shares of Vaxcyte in the first quarter worth about $58,000. Finally, Allworth Financial LP bought a new stake in shares of Vaxcyte in the second quarter worth about $75,000. 96.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Finally, Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Stock Down 1.2%

Vaxcyte stock opened at $61.87 on Tuesday. Vaxcyte, Inc. has a 52-week low of $29.87 and a 52-week high of $65.00. The firm’s fifty day moving average is $56.67 and its 200 day moving average is $55.84. The company has a market cap of $9.21 billion, a price-to-earnings ratio of -8.11 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter in the previous year, the firm earned ($1.22) earnings per share. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.86, for a total transaction of $121,185.00. Following the sale, the chief operating officer directly owned 157,541 shares of the company’s stock, valued at $8,485,158.26. The trade was a 1.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total value of $538,900.00. Following the sale, the chief financial officer directly owned 105,176 shares in the company, valued at $5,667,934.64. The trade was a 8.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 120,646 shares of company stock valued at $6,570,810 over the last quarter. 3.30% of the stock is owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.